Emerging pharmacotherapeutic agents for insomnia: a hypnotic panacea?

被引:5
作者
Navab, Pedram [1 ]
Guilleminault, Christian [1 ]
机构
[1] Stanford Univ, Stanford Sleep Disorders Clin, Sleep Med Program, Stanford, CA 94305 USA
关键词
benzodiazepine receptor agonists; cognitive behavioural therapy; insomnia; latency to persistent sleep; subjective sleep onset latency; total sleep time; wake after sleep onset;
D O I
10.1517/14656566.7.13.1731
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The burden of insomnia has had a significant effect not only on the socioeconomic matrix, but also the medical terrain, as signified by the increased morbidity and mortality of its associated psychiatric and organic sequelae. To this end, a plethora of pharmacotherapeutic agents have been recently introduced that address the vital need to combat insomnia and prevent the perpetuation in its chronic form. The previously and currently dispensed barbiturates and benzodiazepines, respectively, have paved the way for newer agents that are purported to be just as effective, or even more so, with a favourable profile in all domains of sleep. In assessing both published clinical studies and unpublished reports conducted on these emerging agents, this article profiles the most contemporary, therapeutic options in lieu of older hypnotics, over-the-counter medications and supplements. Furthermore, this paper aims to indicate both the future course of hypnotics and the developments currently in progress.
引用
收藏
页码:1731 / 1738
页数:8
相关论文
共 28 条
[1]  
[Anonymous], 2005, MED LETT DRUGS THER, V47, P89
[2]   Zolpidem for persistent insomnia in SSRI-treated depressed patients [J].
Asnis, GM ;
Chakraburtty, A ;
DuBoff, EA ;
Krystal, A ;
Londborg, PD ;
Rosenberg, R ;
Roth-Schechter, B ;
Scharf, MB ;
Walsh, JK .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (10) :668-676
[3]   Oral trazodone is not effective therapy for erectile dysfunction: A double-blind, placebo controlled trial [J].
Costabile, RA ;
Spevak, M .
JOURNAL OF UROLOGY, 1999, 161 (06) :1819-1822
[4]  
DACOURT G, 1999, J PSYCHOPHARMACOL, V13, P81
[5]   Sleep latency is shortened during 4 weeks of treatment with zaleplon a novel nonbenzodiazepine hypnotic [J].
Elie, R ;
Rüther, E ;
Farr, I ;
Emilien, G ;
Salinas, E .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (08) :536-544
[6]   An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia [J].
Erman, M ;
Seiden, D ;
Zammit, G ;
Sainati, S ;
Zhang, J .
SLEEP MEDICINE, 2006, 7 (01) :17-24
[7]   4-fluorosulfonylpiperidines:: Selective 5-HT2A ligands for the treatment of insomnia [J].
Fish, LR ;
Gilligan, MT ;
Humphries, AC ;
Ivarsson, M ;
Ladduwahetty, T ;
Merchant, KJ ;
O'Connor, D ;
Patel, S ;
Philipps, E ;
Vargas, HM ;
Hutson, PH ;
MacLeod, AM .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (16) :3665-3669
[8]  
GLASS J, BR MED J, V331, P1169
[9]   Doxepin in the treatment of primary insomnia:: A placebo-controlled, double-blind, polysomnographic study [J].
Hajak, G ;
Rodenbeck, A ;
Voderholzer, U ;
Riemann, D ;
Cohrs, S ;
Hohagen, F ;
Berger, M ;
Rüther, E .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (06) :453-463
[10]   Epidemiology of DSM-IV insomnia in adolescence: Lifetime prevalence, chronicity, and an emergent gender difference [J].
Johnson, EO ;
Roth, T ;
Schultz, L ;
Breslau, N .
PEDIATRICS, 2006, 117 (02) :E247-E256